![]() |
ALK Negative Anaplastic Large Cell Lymphoma |
Credits: 1.00 Post-Assessment Questions: 7
Release Date: 5 Oct 2020
Expiration Date: 2 Sep 2021
Last Reviewed: 2 Sep 2020
Estimated Time To Finish: 60 Minutes
Need Help? If you have a system or content concerns, please contact support@statpearls.com, or call (727) 289-9796.
ALK-negative anaplastic large cell lymphoma (ALK(-) ALCL) is an uncommon CD30-positive T-cell lymphoma that presents a major diagnostic challenge. It affects individuals in a wide age range and a variety of nodal and extranodal sites. Both morphologically and immunohistochemically, anaplastic large cell lymphoma (ALCL) can mimic many other hematologic and non-hematologic malignancies. This activity explains how to properly evaluate for ALK-negative anaplastic large cell lymphoma and highlights the role of the interprofessional team in caring for patients with this condition.
This activity has been designed to meet the educational needs of nurse practitioners.
At the conclusion of this activity, the learner will be better able to:
Each author, editor, faculty and planning committee member have completed a disclosure form indicating that neither they nor their spouse/partner has a financial interest/arrangement or affiliation that could be perceived as a real or apparent conflict of interest related to the content of this activity.
COMMERCIAL SUPPORT: This activity has received NO commercial support.
Hover over the contributor names to see details and disclosures of any financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.
Authors: Erica Kao, Shiva Kumar Mukkamalla
Editors: David Lynch
Editors-In-Chief: Hector Lopez-CardonaThomas GodwinDavid Lynch
Chief Medical Reviewer: Shiva Kumar Mukkamalla
Nurse Planner/Reviewer/Editor: Lisa Haddad
Nurse Planner/Reviewer/Editor: Bernadette Makar
Nurse Planner/Reviewer/Editor: Dorothy Caputo
Pharmacy Planner/Reviewer/Editor: Mark Pellegrini
Physician Planner/Reviewer/Editor: Scott Dulebohn
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and StatPearls Publishing, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 1.00 contact hour(s) (which includes 0.1 hour(s) of pharmacology).
Cancellation Policy: Cancellations must be received in writing and a money-back guarantee is provided if not completely satisfied.
Equal Opportunity
Medium or Media Used:
Instructions for Credit
StatPearls and AKH adhere to provider standards regarding commercial support of continuing education. It is the policy of StatPearls and AKH that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that authors and editors will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation. Detailed disclosure will be made prior to starting the activity.
The information provided for this activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
The contributors and editors of StatPearls have attested that all associated media (images and video) have been legally cleared for use with this activity. All copyrights are reserved.
5 Star | |
4 Star | |
3 Star | |
2 Star | |
1 Star |
Stay up to date on the latest medical knowledge with 6029 CE activities. In these online self-assessment activities, read our reference articles and test your knowledge with more than 6524.5 hours of CE.